NADAC acquisition cost data for ESTRADIOL VALERATE 100 MG/5 ML. This is a generic medication, typically more affordable than brand-name equivalents.
| Generic Name | Estradiol Valerate |
| Manufacturer | AX Pharmaceutical Corp |
| Dosage Form | POWDER |
| Product Type | BULK INGREDIENT |
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00574087005 | $19.66 | 2022-02-23 | Rx |
| 00574087005 | $19.66 | 2022-02-23 | Rx |
| 00143929001 | $24.04 | 2022-12-21 | Rx |
| 00517042001 | $24.04 | 2022-12-21 | Rx |
| 00143929001 | $24.04 | 2022-12-21 | Rx |
| 00517042001 | $24.04 | 2022-12-21 | Rx |
Generic: Estradiol Valerate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $368.5K | 1,717 | 716 | $38.85 |
| 2020 | $271.6K | 1,365 | 545 | $36.15 |
| 2021 | $255.3K | 1,305 | 576 | $34.91 |
| 2022 | $171.0K | 917 | 409 | $33.67 |
| 2023 | $132.3K | 717 | 293 | $33.55 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $16.5K | 76 | 35 |
| Texas | $10.4K | 56 | 24 |
| Colorado | $8.2K | 33 | 13 |
| Michigan | $7.8K | 37 | 15 |
| Oregon | $7.6K | 36 | 13 |
| Georgia | $7.0K | 42 | 14 |
| Ohio | $5.7K | 32 | N/A |
| Florida | $5.4K | 31 | 15 |
| Connecticut | $5.2K | 31 | N/A |
| Washington | $5.1K | 27 | 12 |
| Pennsylvania | $5.0K | 23 | N/A |
| Arizona | $4.2K | 22 | 11 |
| New York | $4.1K | 28 | N/A |
| North Carolina | $3.5K | 13 | N/A |
| Massachusetts | $3.0K | 13 | N/A |
| Illinois | $2.6K | 17 | N/A |
| Tennessee | $2.5K | 12 | N/A |
| Maryland | $2.4K | 13 | N/A |
| Nebraska | $2.2K | 16 | N/A |
| Wisconsin | $2.1K | 13 | N/A |
| Oklahoma | $1.9K | 18 | N/A |
| Louisiana | $1.9K | 12 | N/A |
| Mississippi | $1.7K | 11 | N/A |
| Kentucky | $1.7K | 11 | N/A |
| Virginia | $1.6K | 11 | N/A |
| Minnesota | $1.5K | 15 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.